Jennifer Lyn Herron
CIK 1675774 · Exec V.P. Chief Comm'l Officer · last filed 2022-10-24
Jennifer Lyn Herron is an Exec V.P. Chief Comm'l Officer who has filed 6 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for CCXI, was dated Oct 24, 2022.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
6
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CCXI | Director | 0 | $14.47 | $0 | $0 | 2 | 2022-10-24 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | — | $0.00 | — | $0 | 1 | 2021-09-28 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Exec V.P. Chief Comm'l Officer | 0 | — | — | $0 | 3 | 2017-02-16 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-24 | CCXI | Disp (D) | −17,237 | $0 | EDGAR |
| 2022-06-30 | CCXI | Grant (A) | +17,237 | $0 | EDGAR |
| 2021-09-28 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-16 | ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Disp (D) | −450 | $0 | EDGAR |
| 2017-02-07 | ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-01 | ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.